News brief­ing: Ax­o­vant faces months of de­lay on lead Parkin­son's gene ther­a­py; Chi­nese CAR-T biotech nabs $100M

One of Ax­o­vant’s top gene ther­a­py prospects for its sec­ond act is hit­ting a road­block that could push its clin­i­cal time­lines back by al­most a year.

In an up­date, the biotech said it was in­formed about de­lays in CMC da­ta and third-part fill-fin­ish is­sues around mid-Oc­to­ber by its man­u­fac­tur­ing part­ner, Ox­ford Bio­med­ica. Ax­o­vant has been de­vel­op­ing a sus­pen­sion-based process for the Parkin­son’s drug; with that tak­ing longer than ex­pect­ed, it now be­lieves “it is un­like­ly that its planned ran­dom­ized, sham-con­trolled tri­al of AXO-Lenti-PD will en­roll pa­tients by the end of cal­en­dar year 2021.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER